Alnylam Pharmace. buy BiotechBee
Start price
07.09.22
/
70%
€208.80
Target price
31.12.24
€300.00
Performance (%)
11.11%
End price
14.12.24
€232.00
Summary
This prediction ended on 14.12.24 with a price of €232.00. The BUY prediction by BiotechBee finished with a performance of 11.11%. BiotechBee has 70% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -3.355% | -3.355% | 42.273% | 54.686% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% | 68.786% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% | 100.066% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% | 43.024% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% | 63.222% |
According to BiotechBee what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy mit Kursziel 300,0